Friday, March 31, 2023
Galapagos and NovAliX announced a strategic collaboration in which Galapagos’ research and discovery capabilities and exclusively related employees based in Romainville, France, will be transferred to NovAliX, a drug discovery-focused Contract Research Organisation. The agreement follows Galapagos’ renewed focus on its key therapeutic areas of oncology and immunology, and the strategic reorientation of the company into a fit-for-purpose research and development (R&D) organisation which aims to accelerate innovation, reduce risks and shorten drug development timelines.
Under the terms of the agreement, NovAliX will acquire Galapagos' drug discovery and research operations in Romainville, France. As a result of the transaction, the Galapagos staff at Romainville, which is solely dedicated to managing these operations, will be transferred to NovAliX, which will be dedicated to taking over all ongoing exploration and discovery activities at Romainville.
The acquisition of Galapagos’ drug discovery and research activities in Romainville, including its highly skilled team, perfectly fits NovAliX in order to complement DNA-Encoded-Libraries database2 and cryo-EM3 driven discovery engine.
